Global Generics Industry Profile & Value Chain Analysis

Global Generics

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

The value chain analysis reveals the business activities which comprise the global generics market value chain. All key stages are highlighted, along with examples of companies active, and assessments of the burning issues for every stage of the value chain. Key value chain stages analyzed include raw ingredients, manufacturing, buyers and end-users.

Synopsis

Essential resource for top-line data and analysis covering the global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.

The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Raw ingredients for generic drugs are often made by the leading pharmaceutical companies. Given the vast number of ingredients used in generics it is not realistically possible for any one company to produce them all.

Manufacturing is dominated by major international pharmaceutical companies, but specialist generic companies exist in the market, although these are often small in scale.

Scope

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the global

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market

– Leading company profiles reveal details of key generics market players' global operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

– Quickly and easily identify the key stages and sub-stages of the global generics market value chain

– See examples of companies active at each stage of the global generics market value chain

– Examine trends and burning issues impacting the global generics market value chain

Reasons to buy

- What was the size of the global generics market by value in 2016?

- What will be the size of the global generics market in 2021?

- What factors are affecting the strength of competition in the global generics market?

- How has the market performed over the last five years?

- How large is the global generics market in relation to its regional counterparts?

- Who are the top competitors in the global generics market?

- What are the key stages and sub-stages of the global generics market value chain?

Table of Contents

Table of Contents

Executive Summary 2

Value chain analysis 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Value Chain Analysis 9

Generics Market complete value chain overview 9

Raw Ingredients 11

Manufacturing 13

Buyers 15

End-Users 17

Market Data 19

Market value 19

Market volume 20

Market Segmentation 21

Geography segmentation 21

Market Outlook 22

Market value forecast 22

Market volume forecast 23

Five Forces Analysis 24

Summary 24

Buyer power 25

Supplier power 26

New entrants 27

Threat of substitutes 28

Degree of rivalry 29

Leading Companies 30

Mylan N.V. 30

Novartis AG 33

Sun Pharmaceutical Industries Ltd 36

Teva Pharmaceutical Industries Limited 39

Methodology 42

Industry associations 43

Related MarketLine research 43

Appendix 44

About MarketLine 44

List of Tables

List of Tables

Table 1: Global generics market value: $ billion, 2012-16 19

Table 2: Global generics market volume: % of total pharma volume, 2012-16 20

Table 3: Global generics market geography segmentation: $ billion, 2016 21

Table 4: Global generics market value forecast: $ billion, 2016-21 22

Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21 23

Table 6: Mylan N.V.: key facts 30

Table 7: Mylan N.V.: key financials ($) 31

Table 8: Mylan N.V.: key financial ratios 31

Table 9: Novartis AG: key facts 33

Table 10: Novartis AG: key financials ($) 34

Table 11: Novartis AG: key financial ratios 34

Table 12: Sun Pharmaceutical Industries Ltd: key facts 36

Table 13: Sun Pharmaceutical Industries Ltd: key financials ($) 37

Table 14: Sun Pharmaceutical Industries Ltd: key financials (Rs.) 37

Table 15: Sun Pharmaceutical Industries Ltd: key financial ratios 37

Table 16: Teva Pharmaceutical Industries Limited: key facts 39

Table 17: Teva Pharmaceutical Industries Limited: key financials ($) 40

Table 18: Teva Pharmaceutical Industries Limited: key financial ratios 40

List of Figures

List of Figures

Figure 1: Generics Market complete value chain overview 9

Figure 2: Generics Market Sector complete value chain with active companies 10

Figure 3: Raw Ingredients – Overview 11

Figure 4: Manufacturing – Overview 13

Figure 5: Buyers – Overview 15

Figure 6: End-Users – Overview 17

Figure 7: Global generics market value: $ billion, 2012-16 19

Figure 8: Global generics market volume: % of total pharma volume, 2012-16 20

Figure 9: Global generics market geography segmentation: % share, by value, 2016 21

Figure 10: Global generics market value forecast: $ billion, 2016-21 22

Figure 11: Global generics market volume forecast: % of total pharma volume, 2016-21 23

Figure 12: Forces driving competition in the global generics market, 2016 24

Figure 13: Drivers of buyer power in the global generics market, 2016 25

Figure 14: Drivers of supplier power in the global generics market, 2016 26

Figure 15: Factors influencing the likelihood of new entrants in the global generics market, 2016 27

Figure 16: Factors influencing the threat of substitutes in the global generics market, 2016 28

Figure 17: Drivers of degree of rivalry in the global generics market, 2016 29

Figure 18: Mylan N.V.: revenues & profitability 31

Figure 19: Mylan N.V.: assets & liabilities 32

Figure 20: Novartis AG: revenues & profitability 34

Figure 21: Novartis AG: assets & liabilities 35

Figure 22: Sun Pharmaceutical Industries Ltd: revenues & profitability 38

Figure 23: Sun Pharmaceutical Industries Ltd: assets & liabilities 38

Figure 24: Teva Pharmaceutical Industries Limited: revenues & profitability 40

Figure 25: Teva Pharmaceutical Industries Limited: assets & liabilities 41

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports